为了估计肝脏成像报告与数据系统 (LI-RADS, LR) v2018 在肝细胞癌 (HCC) 筛查中所报告的 CT 或 MRI 的患病率，本回顾性研究纳入了所有在 2018 年 8 月至 2020 年 4 月期间进行 HCC 筛查的患者的 CT 和 MRI 报告。排除了在索引检查前两年内进行过腹部超声、CT 或 MRI 的患者。从每份放射学报告中提取了所报告的肝脏观察数以及每个观察的 LI-RADS v2018 类别。共有 329 名患者（男性 170 人 [52%]，平均年龄 59 岁 [标准差为 12]），其中有 177 人 (54%) 进行了 gadoxetate 强化的 MRI，72 人 (22%) 进行了胞外对比度增强的 MRI，7 人 (2%) 进行了未指定对比剂的 MRI，73 人 (22%) 进行了 CT。在 329 名患者中，有 199 人 (60%) 没有报告的观察结果；130 名患者报告了 166 个观察结果：114 个 (68.7%) 为 LR-1，8 个 (4.8%) 为 LR-2，21 个 (12.6%) 为 LR-3，6 个 (3.6%) 为 LR-4，13 个 (7.8%) 为 LR-5，3 个 (1.8%) 为 LR-M，1 个 (0.6%) 为 LR-TIV。在 114 个 LR-1 观察中，有 78 个 (68%) 为囊肿，17 个 (15%) 为血管瘤，12 个 (11%) 为血管分流，3 个 (3%) 为局灶性结节增生，2 个 (2%) 为铁染色结节，1 个 (1%) 为脂肪瘤，1 个 (1%) 为胆管畸形瘤。共有 23 个观察结果属于可能或明确的恶性类别（LR-4、LR-5、LR-M 或 LR-TIV），在 20/329 (6%) 的患者中报告。在接受 CT/MRI 强化筛查的风险人群中，60% 的患者没有肝脏观察结果，6% 的患者有可能或明确的恶性观察结果。CT 或 MR 检查中 LI-RADS v2018 类别的患病率有助于制定筛查标准并评估 CT 和 MRI 的监测策略的经济效益。© 2023. 作者独家许可给施普林格科技及商业媒体有限公司（Springer Science+Business Media, LLC）的一部分。

To estimate the prevalence of Liver Imaging Reporting and Data System (LI-RADS, LR) v2018 categories reported on CT or MRI performed for hepatocellular carcinoma (HCC) screening.This retrospective study included all reports for CT and MRI exams performed for HCC screening patients between 8/2018 and 4/2020. Patients with ultrasound, CT, or MRI of the abdomen within two years of the index exam were excluded. From each radiology report, we extracted number of reported liver observations, and LI-RADS v2018 category for each observation.There were 329 patients (170 [52%] male, mean age 59 years [SD 12]), of whom 177 (54%) had MRI with gadoxetate, 72 (22%) had MRI with extracellular contrast, 7 (2%) had MRI with unspecified contrast, and 73 (22%) had CT. Of 329 patients, 199 (60%) had no reported observations; 130 patients had 166 reported observations: 114 (68.7%) LR-1, 8 (4.8%) LR-2, 21 (12.6%) LR-3, 6 (3.6%) LR-4, 13 (7.8%) LR-5, 3 (1.8%) LR-M, and 1 (0.6%) LR-TIV. Of 114 LR-1 observations, 78 (68%) were cysts, 17 (15%) were hemangiomas, 12 (11%) were vascular shunts, 3 (3%) were focal nodular hyperplasia, 2 (2%) were siderotic nodules, 1 (1%) was a lipoma, and 1 (1%) was biliary hamartoma. There were 23 observations with probably or definitely malignant categories (LR-4, LR-5, LR-M or LR- TIV), reported in 20/329 (6%) of patients.In a cohort of at-risk patients undergoing contrast-enhanced CT/MRI for HCC screening, 60% of had no liver observations, and 6 % had probably or definitely malignant observations.The prevalence of LI-RADS v2018 categories on CT or MR exams used for HCC screening can help develop screening criteria and assess cost-effectiveness of surveillance strategies with CT and MRI.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.